Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas
about
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potentialPhase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transportRole of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cellsPreclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.Observational Evaluations of Mice during Cerebral Microdialysis for Pediatric Brain Tumor ResearchBreast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team upTyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.Toward a new age of cellular pharmacokinetics in drug discovery.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Animal models for glioma drug discovery.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling.Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer.Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.Three- and four-class classification models for P-glycoprotein inhibitors using counter-propagation neural networks.Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.
P2860
Q28484249-50369906-5AD6-4DC3-B13F-2E2B9EEF229CQ33412801-046B1383-7B8B-4E65-AAA6-2BF22E51E3F8Q33860877-7BDFF481-63CC-41AA-9540-5C0C92003081Q34472367-26199260-4D29-4012-8B8D-1300E1AB6A45Q34977187-91694507-A2E8-4AF1-BFE2-363F28BA39C8Q34988108-A3C924F1-82DC-4FD1-A3F5-F8758F701983Q35572057-9B03D2DB-3900-448A-80D2-0EF0E610140EQ35702254-833C6D3D-F8F8-425E-AD7E-F9180354F95DQ35720625-1107D91B-0B9E-4FFF-B926-E03D568E9F29Q35946822-0B687F05-327C-4D6C-AF8E-DCE94AF24CA7Q36136128-74B90968-ED30-48CF-9139-557F45BA1EAEQ36312901-803C9FCF-83CB-4A17-A36C-F49D7C45B077Q37714896-5293076B-EFB2-4E23-9CB0-33D142E3273CQ37851981-C14F020D-B40A-422E-A6A5-E8B66B561CCDQ37853578-6522AA2E-769E-4A17-B95F-A19FE8C0E762Q38014575-5DE9ECDE-303D-4A97-B16F-B553324CCE35Q38207943-F615AA03-75BA-4328-AFDC-8CF5E68A1398Q39138906-25DCE678-A1FE-4B45-B8DD-0F9331195F3AQ39387222-654EB8CE-92D1-4A18-9B45-B97DB5B63A48Q39393941-C595338D-B43D-42A3-8FC9-A87F00BBF02AQ41215905-88558B74-6C58-4178-B360-76706BD22857Q42563392-BC069AEC-0CB9-44F6-B0AF-F7FBE64865D7Q47832898-8722599A-B223-475F-B3F9-C7C4AC0924C0Q50784573-6D47FDAE-7CF2-4A76-BFB2-25589E10EDA2Q50976814-0442DAC4-E9D7-404F-86B0-A78876510A81Q53265222-58AAD043-0ABD-4078-A249-9F1E26C56825Q54969600-1EFCD127-188B-430E-8A35-2697472FAD27
P2860
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas
@en
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
@nl
type
label
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas
@en
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
@nl
prefLabel
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas
@en
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
@nl
P2093
P2860
P1433
P1476
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas
@en
P2093
Angel M Carcaboso
Christopher Calabrese
Christopher M Waters
Clinton F Stewart
Lorraine Tracey
Mohamed A Elmeliegy
Stephen J Juel
Ziwei M Zhang
P2860
P304
P356
10.1158/0008-5472.CAN-09-4264
P407
P577
2010-05-11T00:00:00Z